Annual FCF
-$76.53 M
+$93.81 M+55.07%
31 December 2023
Summary:
Amicus Therapeutics annual free cash flow is currently -$76.53 million, with the most recent change of +$93.81 million (+55.07%) on 31 December 2023. During the last 3 years, it has risen by +$129.84 million (+62.92%). FOLD annual FCF is now -626.96% below its all-time high of $14.52 million, reached on 31 December 2007.FOLD Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$23.33 M
-$44.92 M-208.03%
30 September 2024
Summary:
Amicus Therapeutics quarterly free cash flow is currently -$23.33 million, with the most recent change of -$44.92 million (-208.03%) on 30 September 2024. Over the past year, it has dropped by -$25.05 million (-1450.72%). FOLD quarterly FCF is now -155.25% below its all-time high of $42.22 million, reached on 31 December 2007.FOLD Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$31.51 M
+$16.59 M+34.48%
30 September 2024
Summary:
Amicus Therapeutics TTM free cash flow is currently -$31.51 million, with the most recent change of +$16.59 million (+34.48%) on 30 September 2024. Over the past year, it has increased by +$45.02 million (+58.82%). FOLD TTM FCF is now -257.16% below its all-time high of $20.05 million, reached on 30 June 2008.FOLD TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FOLD Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -1450.7% | +58.8% |
| 3 y3 years | +62.9% | +67.7% | +84.7% |
| 5 y5 years | +71.7% | +66.1% | +88.3% |
FOLD Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +62.9% | -208.0% | +72.0% | at high | +84.7% |
| 5 y | 5 years | at high | +71.7% | -208.0% | +78.5% | at high | +89.4% |
| alltime | all time | -627.0% | +75.0% | -155.3% | +82.8% | -257.2% | +90.7% |
Amicus Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$23.33 M(-208.0%) | -$31.51 M(-34.5%) |
| June 2024 | - | $21.59 M(-168.5%) | -$48.10 M(-45.4%) |
| Mar 2024 | - | -$31.51 M(-1924.3%) | -$88.03 M(+15.0%) |
| Dec 2023 | -$76.53 M(-55.1%) | $1.73 M(-104.3%) | -$76.53 M(-52.7%) |
| Sept 2023 | - | -$39.91 M(+117.7%) | -$161.71 M(+21.3%) |
| June 2023 | - | -$18.34 M(-8.4%) | -$133.28 M(+1.6%) |
| Mar 2023 | - | -$20.01 M(-76.0%) | -$131.17 M(-23.0%) |
| Dec 2022 | -$170.34 M(-17.5%) | -$83.45 M(+626.3%) | -$170.34 M(+7.0%) |
| Sept 2022 | - | -$11.49 M(-29.2%) | -$159.17 M(-7.6%) |
| June 2022 | - | -$16.22 M(-72.6%) | -$172.27 M(-10.4%) |
| Mar 2022 | - | -$59.19 M(-18.1%) | -$192.34 M(-6.8%) |
| Dec 2021 | -$206.38 M(-12.7%) | -$72.27 M(+193.9%) | -$206.38 M(+11.6%) |
| Sept 2021 | - | -$24.59 M(-32.2%) | -$184.99 M(-8.7%) |
| June 2021 | - | -$36.29 M(-50.4%) | -$202.69 M(+0.8%) |
| Mar 2021 | - | -$73.22 M(+43.9%) | -$200.99 M(-15.0%) |
| Dec 2020 | -$236.52 M(-12.5%) | -$50.89 M(+20.3%) | -$236.52 M(-7.0%) |
| Sept 2020 | - | -$42.29 M(+22.3%) | -$254.38 M(-6.3%) |
| June 2020 | - | -$34.59 M(-68.2%) | -$271.62 M(-8.8%) |
| Mar 2020 | - | -$108.75 M(+58.2%) | -$297.69 M(+10.1%) |
| Dec 2019 | -$270.43 M(-11.7%) | -$68.76 M(+15.5%) | -$270.43 M(+2.4%) |
| Sept 2019 | - | -$59.53 M(-1.8%) | -$264.08 M(-22.3%) |
| June 2019 | - | -$60.65 M(-25.6%) | -$340.01 M(+0.8%) |
| Mar 2019 | - | -$81.49 M(+30.6%) | -$337.41 M(+10.2%) |
| Dec 2018 | -$306.26 M(+40.3%) | -$62.41 M(-53.9%) | -$306.26 M(-3.7%) |
| Sept 2018 | - | -$135.45 M(+133.3%) | -$318.01 M(+36.7%) |
| June 2018 | - | -$58.06 M(+15.3%) | -$232.58 M(+6.7%) |
| Mar 2018 | - | -$50.34 M(-32.1%) | -$217.99 M(-0.1%) |
| Dec 2017 | -$218.22 M(+39.8%) | -$74.16 M(+48.3%) | -$218.22 M(+23.9%) |
| Sept 2017 | - | -$50.02 M(+15.1%) | -$176.09 M(+4.9%) |
| June 2017 | - | -$43.46 M(-14.1%) | -$167.85 M(+5.7%) |
| Mar 2017 | - | -$50.58 M(+57.9%) | -$158.86 M(+1.8%) |
| Dec 2016 | -$156.10 M(+48.7%) | -$32.03 M(-23.4%) | -$156.10 M(-3.7%) |
| Sept 2016 | - | -$41.79 M(+21.3%) | -$162.15 M(+14.0%) |
| June 2016 | - | -$34.47 M(-27.9%) | -$142.19 M(+8.5%) |
| Mar 2016 | - | -$47.81 M(+25.6%) | -$131.04 M(+24.9%) |
| Dec 2015 | -$104.96 M | -$38.08 M(+74.4%) | -$104.96 M(+28.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | -$21.83 M(-6.3%) | -$81.43 M(+8.9%) |
| June 2015 | - | -$23.31 M(+7.3%) | -$74.78 M(+18.0%) |
| Mar 2015 | - | -$21.73 M(+49.3%) | -$63.38 M(+22.1%) |
| Dec 2014 | -$51.91 M(+11.7%) | -$14.55 M(-4.1%) | -$51.91 M(+14.0%) |
| Sept 2014 | - | -$15.18 M(+27.5%) | -$45.52 M(+3.6%) |
| June 2014 | - | -$11.91 M(+16.1%) | -$43.92 M(+3.4%) |
| Mar 2014 | - | -$10.26 M(+25.6%) | -$42.48 M(-8.6%) |
| Dec 2013 | -$46.49 M(+22.1%) | -$8.17 M(-39.9%) | -$46.49 M(+1.4%) |
| Sept 2013 | - | -$13.58 M(+29.8%) | -$45.85 M(+15.5%) |
| June 2013 | - | -$10.46 M(-26.7%) | -$39.70 M(-3.7%) |
| Mar 2013 | - | -$14.27 M(+89.5%) | -$41.22 M(+8.3%) |
| Dec 2012 | -$38.07 M(-25.1%) | -$7.53 M(+1.4%) | -$38.07 M(-13.6%) |
| Sept 2012 | - | -$7.43 M(-38.0%) | -$44.08 M(-11.6%) |
| June 2012 | - | -$11.99 M(+7.8%) | -$49.86 M(+2.6%) |
| Mar 2012 | - | -$11.12 M(-17.9%) | -$48.59 M(-4.4%) |
| Dec 2011 | -$50.84 M(+253.9%) | -$13.54 M(+2.6%) | -$50.84 M(+236.2%) |
| Sept 2011 | - | -$13.20 M(+23.2%) | -$15.12 M(+16.0%) |
| June 2011 | - | -$10.72 M(-19.9%) | -$13.04 M(-8.5%) |
| Mar 2011 | - | -$13.38 M(-160.3%) | -$14.25 M(-0.8%) |
| Dec 2010 | -$14.37 M(-68.2%) | $22.18 M(-299.4%) | -$14.37 M(-69.6%) |
| Sept 2010 | - | -$11.12 M(-6.7%) | -$47.22 M(-1.3%) |
| June 2010 | - | -$11.92 M(-11.7%) | -$47.85 M(+1.5%) |
| Mar 2010 | - | -$13.50 M(+26.4%) | -$47.16 M(+4.4%) |
| Dec 2009 | -$45.18 M(+14.3%) | -$10.68 M(-9.2%) | -$45.18 M(-9.3%) |
| Sept 2009 | - | -$11.76 M(+4.7%) | -$49.80 M(+7.6%) |
| June 2009 | - | -$11.23 M(-2.5%) | -$46.28 M(+5.9%) |
| Mar 2009 | - | -$11.52 M(-24.7%) | -$43.69 M(+10.5%) |
| Dec 2008 | -$39.53 M(-372.2%) | -$15.30 M(+86.0%) | -$39.53 M(-319.7%) |
| Sept 2008 | - | -$8.23 M(-4.8%) | $17.99 M(-10.3%) |
| June 2008 | - | -$8.64 M(+17.4%) | $20.05 M(+10.8%) |
| Mar 2008 | - | -$7.36 M(-117.4%) | $18.11 M(+24.7%) |
| Dec 2007 | $14.52 M(-140.4%) | $42.22 M(-784.2%) | $14.52 M(-152.4%) |
| Sept 2007 | - | -$6.17 M(-41.7%) | -$27.70 M(+28.7%) |
| June 2007 | - | -$10.59 M(-3.2%) | -$21.53 M(+96.8%) |
| Mar 2007 | - | -$10.94 M | -$10.94 M |
| Dec 2006 | -$35.92 M(+69.7%) | - | - |
| Dec 2005 | -$21.16 M | - | - |
FAQ
- What is Amicus Therapeutics annual free cash flow?
- What is the all time high annual FCF for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly FCF year-on-year change?
- What is Amicus Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Amicus Therapeutics?
- What is Amicus Therapeutics TTM FCF year-on-year change?
What is Amicus Therapeutics annual free cash flow?
The current annual FCF of FOLD is -$76.53 M
What is the all time high annual FCF for Amicus Therapeutics?
Amicus Therapeutics all-time high annual free cash flow is $14.52 M
What is Amicus Therapeutics quarterly free cash flow?
The current quarterly FCF of FOLD is -$23.33 M
What is the all time high quarterly FCF for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly free cash flow is $42.22 M
What is Amicus Therapeutics quarterly FCF year-on-year change?
Over the past year, FOLD quarterly free cash flow has changed by -$25.05 M (-1450.72%)
What is Amicus Therapeutics TTM free cash flow?
The current TTM FCF of FOLD is -$31.51 M
What is the all time high TTM FCF for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM free cash flow is $20.05 M
What is Amicus Therapeutics TTM FCF year-on-year change?
Over the past year, FOLD TTM free cash flow has changed by +$45.02 M (+58.82%)